A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)
NCT01314664
·
clinicaltrials.gov ↗
TERMINATED
Status
15
Enrollment
INDUSTRY
Sponsor class
Stopped
Business decision, not safety related
Conditions
Bladder Cancer
CIS
Sponsor
Endo Pharmaceuticals